Literature DB >> 7259792

Contribution of cyanate to the albumin binding defect of uremia.

K Bachmann, M Valentovic, R Shapiro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7259792     DOI： 10.1016/0006-2952(81)90442-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  5 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents.

Authors:  C Aguirre; J M Rodríguez-Sasiain; R Calvo
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin.

Authors:  T J Dengler; G M Robertz-Vaupel; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.

Authors:  L A Marcantonio; W H Auld; W R Murdoch; R Purohit; G G Skellern; C A Howes
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

5.  Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies.

Authors:  Shuichiro Nakabo; Motomu Hashimoto; Shinji Ito; Moritoshi Furu; Hiromu Ito; Takao Fujii; Hajime Yoshifuji; Yoshitaka Imura; Ran Nakashima; Kosaku Murakami; Nobuo Kuramoto; Masao Tanaka; Junko Satoh; Akihito Ishigami; Satoshi Morita; Tsuneyo Mimori; Koichiro Ohmura
Journal:  Rheumatology (Oxford)       Date:  2017-07-01       Impact factor: 7.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.